Bayer Healthcare LLC

Second Genome, Inc.

Ye Jin

Terry Hermiston

Andrew Wonhee Han

Toshihiko Takeuchi

Uwe Gritzan

Michael Strerath

Karim Dabbagh

Frank Dittmer

Tarunmeet Gujral

John E Murphy

Andrew Whitman Goodyear

Timothy Myles

Michi Izumi Willcoxon

Stefanie Banas

Todd Zachary Desantis

John R Murphy

Todd Zachary DeSantis

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

Proteins for the treatment of epithelial barrier function disorders

This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin &#x3b2; complexed with heparin and/or heparin-like structure (AT&#x3b2;H). These AT&#x3b2;H binding proteins can block the anti-coagulant activity of AT&#x3b2; to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.

Monoclonal antibodies against antithrombin beta

Provided herein are protein biomarkers for NETosis related diseases, including proteases. Also provided are substrate sequences of such proteases and uses thereof.

Application of N-terminomics to NETosis in inflammation

Monoclonal antibodies against antithrombin &#x3b2;

Growing community of inventors

San Ramon, CA, United States of America

Ye Jin